Interestingly, in advanced breast cancer patients, reoxygenation of tumor tissue was higher on day 7 following eribulin infusion compared to anti-VEGF antibody (bevacizumab) treatment as measured by diffuse optical spectroscopic imaging (DOSI) (Ueda et al, 2016). Here, VEGFA is linked to breast carcinoma.